Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
#Aduhelm Market Size, Value And Growth Trajectory Through 2030#_x000D_
Historically, expansion has been driven by an increasingly elderly worldwide demographic, the ongoing unavailability of definitive Alzheimer’s disease treatments, progress made in amyloid research, a surge in dementia cases, and an uptick in clinical trials focused on neurological conditions._x000D_
_x000D_
The projected growth during this period is attributable to several factors, including an expanding population of individuals affected by Alzheimer’s disease. A heightened requirement for early intervention treatments also contributes, alongside the wider adoption of diagnostic methods based on biomarkers. Furthermore, increased healthcare expenditures dedicated to neurological conditions and the ongoing development of advanced monoclonal antibodies are key drivers._x000D_
_x000D_
Key trends anticipated in the forecast period involve a stronger emphasis on therapies designed to modify Alzheimer’s disease progression. There is also a rising application of monoclonal antibodies in neurology, coupled with increased financial investment in neurodegenerative research. A significant focus on diagnosing Alzheimer’s at earlier stages and the broadening availability of amyloid-targeting treatments are also notable developments._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Aduhelm Market Demand Drivers Opening New Revenue Streams#_x000D_
The rising prevalence of Alzheimer’s disease is expected to significantly propel the growth of the Aduhelm market. This progressive neurodegenerative disorder, characterized by a decline in cognitive functions such as memory, reasoning, and behavior, is becoming more widespread due to a combination of demographic, medical, and societal factors. Aduhelm (aducanumab-avwa) is employed to treat Alzheimer’s disease by targeting and reducing amyloid-beta plaques in the brain, which are believed to contribute to the disease’s progression. For instance, according to the Alzheimer Society in May 2024, an estimated 982,000 people in the UK are currently living with dementia, a figure projected to increase to 1.4 million by 2040. Therefore, the escalating prevalence of Alzheimer’s disease is a key driver for the expansion of the Aduhelm market._x000D_
_x000D_
#Aduhelm Market Segmentation: How Does The Market Break Down By Category?#_x000D_
The aduhelm market covered in this report is segmented – _x000D_
_x000D_
1) By Indication: Mild Cognitive Impairment, Mild Dementia _x000D_
2) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies_x000D_
3) By End User: Adult, Geriatric_x000D_
_x000D_
#Aduhelm Market Trends Powering Strategic Industry Growth#_x000D_
Leading firms within the Aduhelm sector are concentrating on creating novel solutions, particularly self-injectable monoclonal antibody treatments, to enhance patient ease of use and compliance. These self-administerable options enable individuals to manage their own ongoing therapy using a prefilled pen or syringe, thereby lessening their reliance on in-hospital infusions. An example of this is the 2025 introduction of Leqembi Iqik (lecanemab self-injectable pen) by Eisai and Biogen, a biopharmaceutical partnership from the US and Japan renowned for their expertise in neurological and antibody-driven treatments. Noteworthy attributes of this product encompass a user-friendly prefilled pen suitable for use at home, a dosing schedule specifically tailored for maintenance treatment, safety and tolerability profiles similar to its intravenous counterpart, and a design engineered to alleviate patient concerns about needles._x000D_
_x000D_
#Aduhelm Market Competitive Overview And Top Companies#_x000D_
Major companies operating in the aduhelm market are Biogen Inc., Eisai Co. Ltd. _x000D_
_x000D_
#View The Full Aduhelm Market Report:#_x000D_
_x000D_
#Aduhelm Market Regional Analysis: Which Geography Leads On Revenue?#_x000D_
North America was the largest region in the aduhelm market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aduhelm market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model